Physician profile
Andrew Kurklinsky
NPI 1831350263
$15,444.51
in general payments reported to CMS, 2019-2025
40 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,188 · 2020: $555 · 2021: $3,592 · 2022: $1,292 · 2023: $1,331 · 2024: $1,291 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Consulting Fee: $900 · Travel and Lodging: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.19 |
| Consulting Fee | $900.00 |
| Travel and Lodging | $875.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,467.59 | 2019-2020 | |
| Penumbra, INC. | $2,318.39 | 2021 | |
| Boston Scientific Corporation | $1,640.31 | 2019-2025 | Watchman Flx, Eluvia, Ekosonic |
| Terumo Medical Corporation | $1,478.85 | 2019-2025 | Navicross, Angio-Seal |
| Inari Medical, INC. | $1,345.83 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $662.72 | 2020-2025 | |
| Abiomed | $613.84 | 2024-2025 | Impella |
| Abbott Laboratories | $390.97 | 2020-2024 | Mitraclip |
| Amgen INC. | $381.59 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $359.86 | 2020-2025 | Wainua, Andexxa, Farxiga |
| Medtronic, INC. | $332.45 | 2019-2023 | Integrity |
| Actelion Pharmaceuticals US, INC. | $292.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $285.26 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $231.22 | 2021-2022 | |
| Biotronik INC. | $196.17 | 2021-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kurklinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.